

Table 1: Physician HPV vaccine recommendation frequency (n=151), n(%)						
	Argentina (n=30) n(%)	Korea (n=30) n(%)	Malaysia (n=30) n(%)	South Africa (n=31) n(%)	Spain (n=30) n(%)	Total
Always	22 (73%)	5 (17%)	4(13%)	13 (42%)	23 (77%)	67 (44%)
Most of the time	5 (17%)	5 (17%)	2 (7%)	3 (10%)	0 (0%)	15 (10%)
Sometimes/hardly ever	3 (10%)	18 (60%)	19 (63%)	6 (20%)	2 (7%)	48 (32%)
Never/I only vaccinate when a patient or her parent asks for it	0 (0%)	2 (7%)	4 (13%)	8 (26%)	5 (17%)	19 (13%)
Not yet implemented	0 (0%)	0 (0%)	0 (0%)	1 (3%)	0 (0%)	1 (1%)

Table 2: Physician opinions about HPV vaccine (n = 151), n(%)						
	Argentina (n = 30) n(%)	Korea (n = 30) n(%)	Malaysia (n = 30) n(%)	South Africa (n = 31) n(%)	Spain (n = 30) n(%)	Total
<i>Positive aspects of HPV vaccination</i>						
Protects against cervical cancer	23 (77%)	29 (97%)	26 (87%)	21 (68%)	26 (87%)	125 (83%)
Protects against genital warts	7 (23%)	3 (10%)	16 (53%)	5 (16%)	25 (83%)	56 (37%)
Long-lasting immunity/Prevents other HPV-related outcomes	5 (17%)	6 (20%)	4(13%)	6 (20%)	2 (7%)	23 (15%)
Vaccine is safe/few adverse events	4 (13%)	4 (13%)	0 (0%)	4 (13%)	1 (3%)	13 (9%)
Vaccination could reduce the need for routine cervical cancer screening/vaccination gives providers opportunity to discuss sexual health issues with patients	4 (13%)	0 (0%)	2 (7%)	6 (19%)	1 (3%)	13 (9%)
I have never heard of the HPV vaccine/Nothing/I don't like anything about the HPV vaccine	2 (7%)	0 (0%)	0 (0%)	2 (7%)	4 (13%)	8 (5%)
Patients can receive other vaccinations at the same visit	0 (0%)	0 (0%)	0 (0%)	1 (3%)	0 (0%)	1(1%)
<i>Negative aspects of HPV vaccination</i>						
Cost	14 (47%)	23 (77%)	14 (47%)	8 (26%)	16 (53%)	75 (50%)
Unsafe/causes adverse events	4 (13%)	7 (23%)	5 (16%)	2 (7%)	10 (33%)	28 (19%)
Shot is painful	6 (20%)	5 (17%)	6 (20%)	3 (10%)	4 (13%)	24 (16%)
Don't know/I have never heard of the HPV vaccine/Nothing/I like everything about the HPV vaccine	6 (20%)	1 (3%)	5 (17%)	5 (17%)	6 (20%)	23 (15%)
3 doses/too many doses/Implementation Problems	5 (17%)	4 (13%)	2 (7%)	6 (20%)	2 (7%)	19 (13%)
Vaccination would not reduce need for routine cervical cancer screening/Requires providers to discuss sexual health issues with girls/parents	6 (20%)	0 (0%)	0 (0%)	1 (3%)	6 (20%)	14 (9%)

Negative perceptions/Lack of parental support/Need better awareness/education campaigns	4 (13%)	2 (7%)	1 (3%)	3 (10%)	2 (7%)	12 (8%)
Not enough evidence	8 (27%)	2 (7%)	0 (0%)	0 (0%)	0 (0%)	10 (7%)
Vaccination does not lead to long-lasting immunity	2 (7%)	2 (7%)	0 (0%)	0 (0%)	5 (17%)	9 (6%)
Not approved for all ages	3 (10%)	0 (0%)	0 (0%)	1 (3%)	0 (0%)	4 (3%)
Likelihood of girls having sex would increase if vaccinated	0 (0%)	0 (0%)	0 (0%)	3 (10%)	0 (0%)	3 (2%)

*** As this was a “select all that apply item”, percentages may sum to more than 100.

Table 3: Physician reasons for not always recommending vaccine (n=83), n(%)						
	Argentina (n=8) n (%)	Korea (n=25) n (%)	Malaysia (n=25) n (%)	South Africa (n=18) n (%)	Spain (n=7) n (%)	Total
Cost too high for patients/Hard to determine insurance coverage for HPV vaccine	3 (38%)	12 (48%)	9 (36%)	1 (6%)	1 (14%)	26 (31%)
Lack of time/difficult to discuss sexual issues	0 (0%)	6 (24%)	12 (48%)	2 (11%)	0 (0%)	20 (19%)
Not enough evidence for it/lack of information/not effective, safe, or useful/other	3 (38%)	5 (20%)	1 (4%)	3 (17%)	5 (86%)	17 (20%)
Not yet implemented/available or recently introduced/refused/don't know	0 (0%)	0 (0%)	1 (4%)	10 (56%)	1 (14%)	12 (14%)
Up-front costs of ordering, stocking, and storing HPV vaccine is too high/inadequate or late reimbursement/refrigerator space	1 (13%)	2 (8%)	1 (4%)	0 (0%)	0 (0%)	4 (5%)
Too few patients want HPV vaccine/Hard to recommend HPV vaccine	1 (13%)	0 (0%)	1 (4%)	2 (11%)	0 (0%)	4 (5%)

Table 4: Physician comfort in recommending vaccine and reasons for discomfort (n=151), n(%)						
	Argentina (n=30) n(%)	Korea (n=30) n(%)	Malaysia (n=30) n(%)	South Africa (n=31) n(%)	Spain (n=30) n(%)	Total
<i>Physician comfort in recommending vaccine</i>						
Very comfortable/a little comfortable	25 (83%)	10 (33%)	25 (83%)	26 (84%)	26 (87%)	112 (74%)
A little uncomfortable/very uncomfortable	5 (17%)	20 (67%)	4 (13%)	3 (10%)	4 (13%)	36 (24%)
Refused/don't know	0 (0%)	0 (0%)	0 (0%)	2 (7%)	0 (0%)	2 (1%)
<i>Physician reasons for discomfort in recommending vaccine</i>						
	(n=5) n(%)	(n=20) n(%)	(n=4) n(%)	(n=3) n(%)	(n=4) n(%)	
Costs are too high	2 (40%)	16 (80%)	1 (25%)	0 (0%)	1 (25%)	20 (56%)
Concerns about vaccine safety/side effects	3 (60%)	4 (20%)	0 (0%)	1 (33%)	3 (75%)	11 (31%)
Uncomfortable discussing sexual health/sexually transmitted infections	0 (0%)	7 (35%)	2 (50%)	0 (0%)	0 (0%)	9 (25%)
Unproven efficacy/not enough long term data	4 (80%)	1 (5%)	0 (0%)	1 (33%)	3 (75%)	9 (25%)
Nothing/don't know/other	1 (20%)	4 (20%)	2 (50%)	0 (0%)	1 (25%)	8 (22%)
Vaccine not publicly available/General uncertainty/concerns about vaccine	3 (60%)	0 (0%)	1 (25%)	2 (67%)	0 (0%)	6 (17%)

*** As this was a “select all that apply item”, percentages may sum to more than 100.

Table 5: Factors that would facilitate physicians' recommendations of HPV vaccine (n=151), n(%)						
	Argentina (n=30) n (%)	Korea (n=30) n (%)	Malaysia (n=30) n (%)	South Africa (n=31) n (%)	Spain (n=30) n (%)	Total
Free or low-cost vaccine/vaccine publicly available	10 (33%)	17 (57%)	15 (50%)	8 (26%)	9 (30%)	59 (39%)
More data on vaccine safety	9 (30%)	9 (30%)	3 (10%)	7 (23%)	24 (80%)	52 (34%)
More data on long-term efficacy	8 (27%)	6 (20%)	1 (3%)	4 (13%)	24 (80%)	43 (28%)
School-based program	5 (17%)	12 (40%)	3 (10%)	5 (16%)	0 (0%)	25 (17%)
Parents/family who are supportive of HPV vaccine/Greater demand for the vaccine/Meetings and campaigns targeting parents	9 (30%)	3 (10%)	3 (10%)	7 (23%)	0 (0%)	22 (15%)
More general information/Educational campaigns, promotions and advertisements	0 (0%)	6 (20%)	2 (7%)	8 (26%)	4 (13%)	20 (13%)
Nothing/refused/don't know	3 (10%)	0 (0%)	7 (23%)	1 (3%)	0 (0%)	11 (7%)
No need for booster doses/fewer doses	0 (0%)	5 (17%)	0 (0%)	4 (13%)	0 (0%)	9 (6%)
Other	3 (10%)	2 (7%)	0 (0%)	0 (0%)	1 (3%)	6 (4%)